Who was studied?
The randomized, double-blind trial excluded diabetes. Participants received one of three tirzepatide regimens or placebo, with a dose-escalation period built into the protocol.
- Participants
- 2,539 adults
- Duration
- 72 weeks
- Funding
- Eli Lilly
What did the study find?
At 72 weeks, average weight reductions ranged from 15.0% to 20.9% across tirzepatide groups, compared with 3.1% for placebo.
What should you keep in mind?
Gastrointestinal events were common, especially during escalation. Results concern the studied population and regimens; they should not be treated as a comparison against a different trial.
Why it matters
Read the escalation design, adverse-event data, and analysis methods alongside the headline weight change. Trial regimens are not calculator recommendations.
Tirzepatide Once Weekly for the Treatment of Obesity
Published 2022 · PMID 35658024 · DOI 10.1056/NEJMoa2206038
Summary by Peptide Lit, checked against the original abstract on October 6, 2026. Read the complete paper for detailed methods and safety results. This page explains published research; it does not recommend a treatment or dose.